Ramosetron versus palonosetron in combination with aprepitant and dexamethasone for the control of highly emetogenic chemotherapy-induced nausea and vomiting

被引：0
|
作者：
Kwon, J. H. [1 ]
Kang, J-H. [2 ]
Lee, Y-G. [3 ]
Park, K. U. [4 ]
An, H. J. [5 ]
Sohn, J. [6 ]
Seol, Y. M. [7 ]
Lee, H. [8 ]
Yun, H-J. [9 ,10 ]
Ahn, J. S. [11 ]
Kim, H. J. [12 ]
机构：
[1] Hallym Univ, Kangdong Sacred Heart Hosp, Div Hematooncol, Dept Internal Med,Coll Med, Seoul, South Korea
[2] Catholic Univ Korea, Seoul ST Marys Hosp, Oncol, Seoul, South Korea
[3] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Internal Med, Sch Med, Seoul, South Korea
[4] Keimyung Univ, Sch Med, Internal Med, Dongsan Med Ctr, Daegu, South Korea
[5] Catholic Univ Korea, St Vincents Hosp, Dept Med Oncol, Coll Med, Suwon, South Korea
[6] Yonsei Univ, Div Med Oncol, Dept Internal Med, Coll Med, Seoul, South Korea
[7] Pusan Natl Univ, Sch Med, Internal Med, Pusan Natl Univ Hosp, Busan, South Korea
[8] Ajou Univ, Sch Med, Hematol Oncol, Ajou Univ Hosp, Suwon, South Korea
[9] Chungnam Natl Univ, Sch Med, Daejeon, South Korea
[10] Chungnam Natl Univ Hosp, Dept Internal Med, Daejeon, South Korea
[11] Samsung Med Ctr, Hematol & Oncol, Seoul, South Korea
[12] ASAN Med Ctr, Clin Epidemiol & Biostat, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1705P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study
    Matsuda, Masahide
    Yamamoto, Tetsuya
    Ishikawa, Eiichi
    Akutsu, Hiroyoshi
    Takano, Shingo
    Matsumura, Akira
    NEUROLOGIA MEDICO-CHIRURGICA, 2016, 56 (11) : 698 - 703
  • [42] Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).
    Zhang, Li
    Lu, Shun
    Feng, Ji Feng
    Dechaphunkul, Arunee
    Chessari, Salvatore
    Lanzarotti, Corinna
    Jordan, Karin
    Aapro, Matti S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapies in patients with lung cancer
    Rapoport, B.
    Boice, J. A.
    Brown, C.
    Street, J. C.
    Hardwick, J. S.
    Carides, A. D.
    Gralla, R. J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 519 - 520
  • [44] A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
    Zelek, Laurent
    Debourdeau, Philippe
    Bourgeois, Hugues
    Wagner, Jean Philippe
    Brocard, Fabien
    Lefeuvre-Plesse, Claudia
    Chauffert, Bruno
    Leheurteur, Marianne
    Bachet, Jean-Baptiste
    Simon, Helene
    Mayeur, Didier
    Scotte, Florian
    ONCOLOGIST, 2021, 26 (10): : E1870 - E1879
  • [45] A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
    Winnie Yeo
    F. K. F. Mo
    J. J. S. Suen
    W. M. Ho
    S. L. Chan
    W. Lau
    J. Koh
    W. K. Yeung
    W. H. Kwan
    K. K. C. Lee
    T. S. K. Mok
    A. N. Y. Poon
    K. C. Lam
    E. K. Hui
    B. Zee
    Breast Cancer Research and Treatment, 2009, 113 : 529 - 535
  • [46] Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).
    Hesketh, Paul Joseph
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Alyasova, Anna
    Drobner, Igor
    Gralla, Richard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy
    Xiao, Yang
    Liu, Jun
    Liu, Yang-Chen
    Huang, Xin-En
    Guo, Jian-Xong
    Wei, Wei
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (09) : 3951 - 3954
  • [48] Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy- induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial
    Cheng, Yi
    Wu, Zehua
    Shi, Lishuo
    Shen, Cailu
    Zhang, Jianwei
    Hu, Huabin
    Li, Weiwei
    Cai, Yue
    Xie, Xiaoyu
    Ling, Jiayu
    Zheng, Qin
    Deng, Yanhong
    ECLINICALMEDICINE, 2022, 49
  • [49] A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
    Yeo, Winnie
    Mo, F. K. F.
    Suen, J. J. S.
    Ho, W. M.
    Chan, S. L.
    Lau, W.
    Koh, J.
    Yeung, W. K.
    Kwan, W. H.
    Lee, K. K. C.
    Mok, T. S. K.
    Poon, A. N. Y.
    Lam, K. C.
    Hui, E. K.
    Zee, B.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 113 (03) : 529 - 535
  • [50] Generic Netupitant Plus Palonosetron and Dexamethasone for Prophylaxis of Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Retrospective Study
    Simhadri, Soumya
    Dayyala, Sowmya
    Musinipally, Anjani Devi
    Guram, Lavanya
    Madavi, Mamatha
    Kancha, Ramakrishna
    Puligundla, Krishna Chaitanya
    SOUTH ASIAN JOURNAL OF CANCER, 2024,
12345